Alterity Therapeutics (ASX:ATH) has moved to deepen its leadership bench at a critical moment in its development, appointing veteran pharmaceutical executive Ann Cunningham to its Board of Directors.
The appointment comes as the company sharpens its focus on late-stage clinical progress for its lead candidate and positions itself for the complex transition from development to potential commercialisation.
Cunningham joins as an independent non-executive director, bringing more than two decades of experience across global pharmaceutical and biotechnology organisations. Her career has spanned senior leadership roles with responsibility for commercial strategy, particularly in neurodegenerative disease and psychiatry, areas closely aligned with Alterity’s therapeutic ambitions.
The appointment arrives at a pivotal phase, as company leadership describes it. Alterity is preparing to move its lead asset, ATH434, into Phase 3 development targeting Multiple System Atrophy, a rare and rapidly progressing neurodegenerative condition with significant unmet medical need. The company believes Cunningham’s track record in shaping commercial pathways for innovative therapies will be instrumental as it navigates the demands of late-stage trials and future market entry
Chair Julian Babarczy said, "We are delighted to welcome Ann to the Alterity Board at a pivotal stage in the Company’s evolution as we prepare to advance ATH434 into Phase 3 development. Ann brings an outstanding combination of global pharmaceutical experience, commercial leadership and deep domain expertise in neurodegenerative diseases. Her experience in shaping commercial strategy for innovative therapies will be highly valuable as we position ATH434 for late-stage development and, ultimately, commercialisation. Importantly, Ann’s perspective will strengthen the Board as we focus on executing our Phase 3 program and maximising the value of our pipeline for shareholders."
Cunningham expressed enthusiasm for the role and the company’s direction, saying, "I am excited to join Alterity at such a pivotal time, with promising clinical data driving strong momentum for ATH434 as a potential disease-modifying treatment for patients suffering from neurodegenerative diseases. In MSA, the Company is addressing a significant unmet need, and I look forward to adding my patient-focused experience alongside the Board and management team to support the next phase of growth."
Cunningham is the founder and chief executive of a pharmaceutical consulting firm focused on patient engagement and improved health outcomes, particularly within underserved populations. Her career includes key contributions to major product launches and portfolio strategies, including work on widely recognised treatments in psychiatry and neurology. She has also held executive roles guiding commercial development at major pharmaceutical companies and currently serves on the board of another biotechnology firm.